MSB's failure was their selection of primary endpoints. NSB's...

MSB's failure was their selection of primary endpoints. NSB's failure was the active drug ingredient. Both of which PR had no input in. PAR's failure to date is the hay fever trial, and while OA is no sure thing, there is a lot of information and data that suggests iPPS could one day be a treatment for OA.

I've been looking at the history of PAR and iPPS to try to understand how this company came about. I know PR introduced iPPS to mesoblast to use in combination with mesenchymal cells, and later used iPPS to successfully treat his own OA. But what made PR establish PAR and pursue the OA avenue? Was it use of iPPS in animal OA or information in the literature or earlier OA patents? Or was it a meeting with Peter Ghosh or benepharmachem or a combination of all?

While it's easy to connect the dots moving backwards, PR appears to have shown considerable foresight to pursue to iPPS and OA link.